Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1481-1500 of 1,782 trials

Refractory Solid Tumors: Propranolol and Vinorelbine Study

We are testing a combination of Propranolol and Vinorelbine in children and teenagers with hard-to-treat solid tumors. The study aims to find the safest dose and evaluate how well this treatment works over time.

Malignant GliomaMalignant Solid TumorDesmoid Tumor>2 yearsSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

Ozone Treatment for Numbness from Chemotherapy

We are studying whether adding ozone therapy helps reduce numbness and tingling in patients with chemotherapy-induced nerve damage. The trial also looks at how this treatment affects overall quality of life and costs.

Chemotherapy-Induced Peripheral Neuropathy6-12 monthsEfficacy phase (II)Confirmation phase (III)>20 visitsStandard MedicinesInternal MedicineNeurologyOncology

Advanced Lung Cancer: Atezolizumab vs. Atezolizumab Plus Bevacizumab

We are studying whether adding bevacizumab to atezolizumab helps patients with advanced non-small-cell lung cancer live longer than using atezolizumab alone. This trial is for those with high PD-L1 expression who have not yet received treatment.

Advanced Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Pembrolizumab for Advanced Adrenocortical Carcinoma

We are studying whether pembrolizumab can effectively treat advanced, progressive adrenocortical carcinoma. The trial also looks at its safety and how it affects patients' quality of life.

Adrenocortical Carcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Heart Attack Recovery: Ferric Carboxymaltose Treatment

We are studying whether intravenous ferric carboxymaltose can improve survival and quality of life in iron-deficient patients who recently had a heart attack. This trial compares its effects to a placebo treatment.

Recent Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCardiologyInternal Medicine

Alzheimer’s Disease: Dimethyl Fumarate Study

We are investigating whether dimethyl fumarate can improve memory and daily activities in patients with mild cognitive impairment and Alzheimer's disease. This study will also assess its effects on brain health and quality of life.

Alzheimer's Disease1-2 yearsEfficacy phase (II)Standard MedicinesNeurologyPsychiatry

Multiple Myeloma: Isatuximab Treatment Study

We are studying a new treatment combination for elderly patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see if this approach improves disease control and safety compared to standard treatments.

Newly Diagnosed Multiple Myeloma in Elderly Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Crohn's Disease: Cellvizio Imaging Study

We are testing a new imaging technique during surgery for Crohn's disease to help identify healthy tissue margins. This may improve surgical outcomes by ensuring enough healthy tissue is removed.

Crohn's Disease>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

NSTEMI Treatment: Aspirin vs. Aspirin and Fondaparinux

We are comparing the effects of aspirin alone to a combination of aspirin and fondaparinux in patients with NSTEMI. This study aims to see which treatment is more effective and safer before invasive procedures.

Non-ST-Elevation Myocardial Infarction (NSTEMI)>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Unruptured Intracranial Aneurysms: Low-Dose Aspirin and Blood Pressure Management

We are studying whether a treatment plan with low-dose aspirin and strict blood pressure control can lower the risk of aneurysm rupture or growth in patients with unruptured intracranial aneurysms. This trial compares this approach to standard care to see if it offers better outcomes.

Unruptured Intradural Aneurysm>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCardiologyNeurology

BOTOX® for Preventing Pancreatic Fistula After Surgery

We are studying whether BOTOX® injections before surgery can help prevent complications in patients undergoing distal pancreatectomy. This trial will assess the safety and effectiveness of this approach.

Postoperative Pancreatic Fistulas≤3 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Retinoblastoma: New Conservative Treatment Approaches

We are studying different chemotherapy and local treatment methods for children with retinoblastoma to see if they can preserve vision without using radiation. This trial includes various patient groups based on their specific conditions.

RetinoblastomaEfficacy phase (II)No PlaceboStandard MedicinesOncologyOphthalmology

Lymphoma: Comparing Pneumococcal Vaccines

We are studying the effectiveness of two pneumococcal vaccines in adults with lymphoma receiving chemotherapy. This trial aims to see which vaccination strategy provides a better immune response and is safer.

Lymphoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesOncology

Lung Cancer Treatment: Immunotherapy and Radiation

We are studying a new treatment combining immunotherapy and radiation for elderly or unfit patients with advanced lung cancer. The aim is to see if this approach improves survival and quality of life.

Unresectable Stage III Non-Small Cell Lung Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Myeloma Treatment: Elranatamab vs. Daratumumab

We are studying whether elranatamab combined with lenalidomide helps patients with newly diagnosed myeloma maintain remission better than daratumumab with lenalidomide after a transplant. This trial will also assess safety and quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

TOASST Study: Comparing Steroid Withdrawal Methods

We are studying whether stopping glucocorticoids suddenly is as safe as tapering them for patients with inflammatory disorders. This research may help improve treatment strategies and patient outcomes.

Inflammatory or Autoimmune Disorders>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Statin Therapy for Frail Older Adults After Stroke

We are studying whether starting statin medication helps frail individuals aged 70 and older who have had a recent stroke or transient ischemic attack. The goal is to see if it improves heart health and quality of life.

Ischemic Stroke and Transient Ischemic Attack>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal MedicineNeurology

Ovarian Cancer: Olaparib and Bevacizumab Study

We are studying how well a new test identifies genetic markers in patients with advanced ovarian cancer and whether combining Olaparib with Bevacizumab improves treatment outcomes. This trial aims to evaluate the safety and effectiveness of this drug combination.

Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Metformin for Small Abdominal Aortic Aneurysms

We are studying if taking metformin daily can slow the growth of small abdominal aortic aneurysms in patients without diabetes. This trial also looks at the safety and quality of life for participants.

Small Abdominal Aortic Aneurysm>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

CD20-Positive Acute Lymphoblastic Leukemia: Obinutuzumab vs. Rituximab

We are comparing two treatments, obinutuzumab and rituximab, for adults with newly diagnosed CD20-positive acute lymphoblastic leukemia. The goal is to see which treatment helps more patients achieve complete remission safely.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology